VeriMomrh-oligopeptide-1 é seguro durante a gravidez?
No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
Pregnancy-safe products containing rh-oligopeptide-1
Related ingredients
Frequently asked questions
- rh-oligopeptide-1 é seguro durante a gravidez?
- No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
- rh-oligopeptide-1 é seguro durante a amamentação?
- Same rationale as pregnancy: theoretical concern from growth-factor activity if systemically absorbed, but no evidence of reproductive or lactation-specific toxicity or breast milk transfer. Large peptide size and available topical formulations suggest negligible systemic bioavailability after topical cosmetic use (sources: PubMed, PubChem, CosIng, EWG).
- rh-oligopeptide-1 é seguro para a pele do bebê?
- Hazard and mechanism scores unchanged (no infant-specific data showing reproductive/ developmental toxicity). Exposure score increased by +1 because infant skin has a less mature barrier and higher surface-area-to-weight ratio; if the peptide has any measurable percutaneous uptake the relative exposure in 0–3 yr olds would be higher. No studies demonstrating placental/breastmilk transfer or infant adverse outcomes were found (sources: PubMed, CosIng, PubChem, EWG).
- Como o VeriMom pontua rh-oligopeptide-1?
- O VeriMom pontua rh-oligopeptide-1 em 73/100 (risco baixo) com base no status EU CosIng, classificações de perigo ECHA e estudos revisados por pares no PubMed. Nosso pipeline de pontuação é totalmente transparente.
- Quais são as alternativas seguras a rh-oligopeptide-1 na gravidez?
- Veja nossa lista curada de alternativas seguras a rh-oligopeptide-1 com base em função semelhante e classificação sem riscos conhecidos.
Verifique qualquer rótulo em 2 segundos
Baixe o VeriMom grátis — escaneie qualquer produto e veja a pontuação de segurança na gravidez instantaneamente.
Aviso Médico
Estas informações são apenas para fins educacionais e não constituem aconselhamento médico. As pontuações de segurança são baseadas em dados publicamente disponíveis e podem não refletir todos os riscos. Sempre consulte seu profissional de saúde antes de usar qualquer produto durante a gravidez ou amamentação.